ENCell Co., Ltd. (KOSDAQ:456070)
8,600.00
-190.00 (-2.16%)
Jun 10, 2026, 3:30 PM KST
ENCell Revenue
ENCell had revenue of 308.93M KRW in the quarter ending March 31, 2026, a decrease of -71.75%. This brings the company's revenue in the last twelve months to 4.47B, down -31.31% year-over-year. In the year 2025, ENCell had annual revenue of 5.26B, down -27.06%.
Revenue (ttm)
4.47B
Revenue Growth
-31.31%
P/S Ratio
21.20
Revenue / Employee
n/a
Employees
n/a
Market Cap
94.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.26B | -1.95B | -27.06% |
| Dec 31, 2024 | 7.21B | -3.32B | -31.51% |
| Dec 31, 2023 | 10.53B | 3.16B | 42.87% |
| Dec 31, 2022 | 7.37B | 3.46B | 88.49% |
| Dec 31, 2021 | 3.91B | 2.50B | 178.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Macrogen | 199.60B |
| ORIENT BIO | 59.09B |
| Amicogen | 43.44B |
| CG Invites | 29.22B |
| GeneOne Life Science | 17.12B |
| Prestige BioPharma | 16.21B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |